Drug Profile
Research programme: antibody-based therapeutics - Austrianni
Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Austrianni
- Class Antibacterials; Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Tuberculosis in Austria (Parenteral)
- 18 Nov 2020 TRIANNI has been acquired by Abcellera
- 06 Sep 2017 Preclinical trials in Tuberculosis in Austria (Parenteral) before September 2017 (Austrianni website, September 2017)